Avanza Fonder AB Buys New Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Avanza Fonder AB bought a new stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 3,043 shares of the biopharmaceutical company's stock, valued at approximately $254,000.

Other institutional investors have also bought and sold shares of the company. Avior Wealth Management LLC boosted its holdings in Intra-Cellular Therapies by 3.0% during the 3rd quarter. Avior Wealth Management LLC now owns 4,473 shares of the biopharmaceutical company's stock worth $327,000 after acquiring an additional 131 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of Intra-Cellular Therapies by 1.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company's stock valued at $748,000 after purchasing an additional 141 shares in the last quarter. Pallas Capital Advisors LLC boosted its holdings in Intra-Cellular Therapies by 6.4% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company's stock worth $266,000 after purchasing an additional 192 shares during the last quarter. Assetmark Inc. grew its position in Intra-Cellular Therapies by 9.1% in the 3rd quarter. Assetmark Inc. now owns 2,477 shares of the biopharmaceutical company's stock worth $181,000 after purchasing an additional 207 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D increased its stake in Intra-Cellular Therapies by 0.6% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 35,673 shares of the biopharmaceutical company's stock valued at $2,610,000 after buying an additional 223 shares during the last quarter. Institutional investors own 92.33% of the company's stock.

Insider Activity at Intra-Cellular Therapies

In other news, President Michael Halstead sold 22,869 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total transaction of $2,038,085.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Sharon Mates sold 51,000 shares of the company's stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. The trade was a 4.55 % decrease in their position. The disclosure for this sale can be found here. 2.60% of the stock is currently owned by corporate insiders.

Intra-Cellular Therapies Trading Down 0.0 %

Shares of NASDAQ ITCI traded down $0.06 during midday trading on Monday, hitting $126.20. The company's stock had a trading volume of 6,016,325 shares, compared to its average volume of 451,954. The firm has a market capitalization of $13.38 billion, a price-to-earnings ratio of -145.06 and a beta of 0.70. The stock has a fifty day moving average price of $89.99 and a 200 day moving average price of $81.30. Intra-Cellular Therapies, Inc. has a one year low of $62.78 and a one year high of $128.00.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $175.40 million for the quarter, compared to the consensus estimate of $172.30 million. During the same period in the previous year, the firm earned ($0.25) EPS. The company's revenue was up 39.0% compared to the same quarter last year. On average, equities research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ITCI has been the topic of a number of research analyst reports. JPMorgan Chase & Co. boosted their target price on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an "overweight" rating in a research note on Monday, November 4th. Needham & Company LLC reissued a "hold" rating and issued a $100.00 price objective on shares of Intra-Cellular Therapies in a research report on Monday, January 13th. Cantor Fitzgerald raised Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, January 14th. Royal Bank of Canada lifted their target price on Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an "outperform" rating in a research note on Friday, October 4th. Finally, Leerink Partnrs lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Six investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $100.31.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.